Evolus (NASDAQ: EOLS) revenue
Evolus reported revenue of $297.2m for fiscal 2025, 11.6% more than in fiscal 2024 ($266.3m).
Evolus has grown its revenue for 6 years in a row, and fiscal 2025 is the highest of its 8 fiscal years on record.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $297.2m | +11.6% | −$32.7m | −11.0% |
| 2024 | $266.3m | +31.8% | −$34.4m | −12.9% |
| 2023 | $202.1m | +36.0% | −$49.2m | −24.4% |
| 2022 | $148.6m | +49.1% | −$65.3m | −44.0% |
| 2021 | $99.7m | +76.3% | −$44.4m | −44.6% |
| 2020 | $56.5m | +61.9% | −$153.1m | −270.7% |
| 2019 | $34.9m | — | −$98.9m | −283.3% |
| 2018 | $0.0m | — | −$46.1m | — |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Evolus revenue compared with its sector
By revenue for its latest fiscal year, Evolus ranks 220th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Evolus, 11.6%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 218th | PROCEPT BioRobotics | $308.1m | 37.2% |
| 219th | Healthstream | $304.1m | 4.3% |
| 220th | Evolus | $297.2m | 11.6% |
| 221st | Ironwood Pharmaceuticals | $296.2m | −15.7% |
| 222nd | Rigel Pharmaceuticals | $294.3m | 64.1% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Evolus
- How much revenue did Evolus make in fiscal 2025?
- Evolus reported revenue of $297.2m for fiscal 2025, compared with $266.3m in fiscal 2024.
- What was the best year for revenue at Evolus?
- Of its last 8 fiscal years, fiscal 2025, with $297.2m.
- Where does Evolus rank in its sector by revenue?
- It ranks 220th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Evolus come from?
- From the annual report (Form 10-K) that Evolus files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Evolus files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018. More on Evolus: the Evolus page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.